Physician profile
Mark M Spatz
NPI 1083803068
$11,550.97
in general payments reported to CMS, 2019-2025
26 companies · $3,356 in 2025
The $3,356 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,028 · 2022: $2,288 · 2023: $2,030 · 2024: $2,849 · 2025: $3,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,147 · Education: $87.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,147.21 |
| Education | $87.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,134.79 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,725.95 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $1,220.90 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $828.85 | 2021-2025 | |
| Leo Pharma INC. | $527.88 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $506.53 | 2022-2024 | Vtama |
| Ucb, INC. | $436.67 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $422.98 | 2024-2025 | Nemluvio, Dysport |
| Arcutis Biotherapeutics, INC. | $372.61 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $350.48 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $342.65 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $274.86 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $216.20 | 2022-2025 | Ebglyss, Taltz |
| Almirall LLC | $199.56 | 2021 | |
| Sun Pharmaceutical Industries INC. | $166.97 | 2021-2023 | Odomzo, Blu-U, Ilumya |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $153.82 | 2022-2025 | Opzelura |
| Helsinn Therapeutics (U.S.), INC. | $131.81 | 2021-2025 | Valchlor |
| Pfizer INC. | $116.41 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $84.04 | 2022 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.48 | 2023-2025 | Spevigo |
| Allergan, INC. | $73.56 | 2021-2022 | |
| Kerecis Limited | $49.35 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Mayne Pharma Commercial LLC | $24.23 | 2025 | |
| Kyowa Kirin, INC. | $16.96 | 2025 | |
| Genentech USA, INC. | $16.44 | 2024 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Spatz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.